# Thymosin Alpha-1: research overview — Immune & Thymic research peptides > A literature summary of Thymosin Alpha-1 (thymalfasin), the lead Immune & Thymic research peptide: mechanism at TLR2/TLR9 and IDO, sepsis and COVID-19 trial data, oncology adjuvant research, and regulatory status. A 28-amino-acid thymic immunomodulator approved internationally as thymalfasin — with a decades-long clinical record, and a landmark 2025 sepsis trial that came back null. ## The short version Thymosin Alpha-1 is a short, highly acidic protein of 28 amino acids, originally purified from calf thymus in 1977 [7]. The synthetic version, thymalfasin, is sequence-identical and is approved as a drug in more than 35 countries for indications ranging from chronic viral hepatitis to immune reconstitution [2]. It is **not** FDA-approved for marketing in the United States. In plain terms, Thymosin Alpha-1 does two things: it helps the immune system respond more effectively when it is underperforming — for example in chronic viral infection, severe sepsis-related T-cell exhaustion, or cancer — and it can simultaneously engage a regulatory pathway that prevents that response from becoming destructive [6]. Think of it as a dial that nudges the immune system toward a more competent and balanced state. A few things are important to hold alongside that summary. First, it is strictly distinct from two other thymic compounds that researchers sometimes conflate with it: thymulin (a zinc-dependent nonapeptide with a completely different structure and receptor pharmacology) and TB-500 (thymosin-β4), which is a different thymosin family protein studied for tissue repair. These are unrelated molecules — the name "thymosin" is a family designation, not a sign of shared biology. Second, the largest and most rigorous clinical trial ever run on Thymosin Alpha-1 — the 2025 phase-3 TESTS trial of 1,106 adults with sepsis — found no significant 28-day mortality benefit [1]. That null result is part of the record and this page reports it without softening. ## What it is Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated polypeptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. Its highly acidic character (no aromatic residues, no disulfide bonds) and the N-terminal acetyl group — essential for biological activity — are what distinguish it chemically. In vivo it is cleaved from a 113-amino-acid precursor protein called prothymosin alpha [2][7]. The synthetic drug thymalfasin is sequence-identical to the endogenous peptide. It was originally isolated and sequenced by Goldstein and colleagues from calf thymus extracts in 1977 and has since accumulated four decades of clinical literature [7][2]. It is available in the US only through investigational or compounding contexts, not as an approved pharmaceutical product. ## How it works Thymosin Alpha-1 operates at the innate-adaptive immune interface through two complementary arms. **The effector arm.** It signals through Toll-like receptors — particularly TLR2 and TLR9 — on dendritic cells and monocytes, promoting their maturation, upregulating antigen-presenting surface molecules (HLA-DR), and driving IL-12 production. Those activated dendritic cells then steer T-cell development toward the Th1 profile (cytotoxic T-cell activity, interferon-gamma output) that is most effective against intracellular pathogens and tumors. This restores T-cell maturation in immunosuppressed states and can reverse T-cell exhaustion — the dysfunctional state where chronically stimulated T cells lose their killing capacity [3][6]. **The regulatory arm.** In parallel, Thymosin Alpha-1 activates the IDO (indoleamine 2,3-dioxygenase) tryptophan-catabolism pathway in dendritic cells — a process that requires TLR9 and type I interferon receptor signaling and generates interleukin-10 and regulatory T cells [6]. The result is a dual signature: enhanced effector immunity in settings of immunosuppression, combined with a tolerogenic brake that can dampen hyperinflammation. This duality is what makes the pharmacology unusually context-sensitive: the balance between the two arms shifts depending on the immune state of the host. ## What the research shows **Biochemical foundation.** The foundational work by Goldstein and colleagues in 1977 isolated Thymosin Alpha-1 from calf thymus (thymosin fraction 5) and determined its complete 28-residue, acetylated sequence — establishing the structural basis for all subsequent pharmacology [7]. **Mechanistic definition.** A pivotal 2006 study in mouse and human dendritic cells mapped the dual immunomodulatory signature: Thymosin Alpha-1 activates IDO tryptophan catabolism via TLR9 and type I interferon receptor signaling, generating a tolerogenic regulatory-T-cell environment even as it drives Th1 priming [6]. That paper established the molecular basis for the peptide's context-dependent behavior. **Sepsis — two trials, diverging results.** The earlier ETASS trial (2013, 361 patients with severe sepsis) reported lower 28-day mortality with Thymosin Alpha-1 versus controls — 26.0% versus 35.0% — accompanied by improved HLA-DR expression on monocytes, though the absolute difference did not reach conventional statistical significance with its primary analysis [5]. The definitive response was the 2025 TESTS trial (1,106 adults, 22 centres, double-blind, placebo-controlled, phase 3): 28-day all-cause mortality was 23.4% in the thymalfasin group versus 24.1% for placebo, hazard ratio 0.99 (95% CI 0.77–1.27), P=0.93 — a null result [1]. Taken together, the sepsis story is one of a hopeful earlier signal that did not replicate at scale. **COVID-19.** A retrospective cohort study of 76 patients with severe COVID-19 reported significantly lower mortality in the Thymosin Alpha-1 group (11.1% versus 30.0%, P=0.044), alongside restoration of blood T-cell numbers in patients with severe lymphocytopenia and reversal of T-cell exhaustion markers (reduced PD-1 and Tim-3 expression on CD8+ T cells) [3]. The retrospective, single-institution design limits causal inference, and later systematic reviews of the broader COVID-19 literature found inconsistent effects. **Oncology.** A 2019 reappraisal positioned Thymosin Alpha-1 as an immunostimulatory adjuvant in oncology — studied in combination with chemotherapy and checkpoint inhibitors for melanoma, hepatocellular carcinoma, and lung cancer. The proposed mechanisms include helping dendritic cells convert a "cold" (immunologically excluded) tumor microenvironment toward one more accessible to immune attack, and potentially mitigating checkpoint-inhibitor toxicity by engaging the IDO-regulatory arm [4]. **Safety and tolerability.** A comprehensive review of four decades of clinical literature characterizes thymalfasin as generally well tolerated, with the dominant adverse effects being mild local reactions at the injection site — redness, itching, or brief stinging — across hundreds of thousands of treated patients, with no documented organ toxicity at studied doses [2]. ## Reported effects, cautions & safety **What community members report (anecdotal, not clinical evidence).** In peptide research communities and on drugs.com and WebMD user forums, the most commonly described anecdotal benefit is catching fewer respiratory illnesses over a season or recovering from them more quickly. A less specific report — a general sense of being more "resilient" or harder to knock down — is also common but highly subjective and vulnerable to expectation effects. Some people dealing with post-viral fatigue or chronic immune complaints describe steadier daytime energy during a course. On the adverse side, the single most common complaint mirrors the clinical literature: mild injection-site redness, itching, or brief stinging. A minority describe a short-lived flu-like or mildly achy day early in a course. A notable minority report noticing no effect at all — unsurprising for an immune modulator whose actions are biochemical rather than perceptible. More informed community members have noted the null 2025 sepsis trial and expressed tempered expectations. **Cautions grounded in the literature.** - *Theoretical caution in autoimmune disease.* Thymosin Alpha-1 promotes dendritic-cell maturation and cytotoxic T-cell activity; broadly enhancing effector immunity is a theoretical concern in established autoimmunity, even though circulating Thymosin Alpha-1 levels are reduced in several autoimmune diseases and the IDO-regulatory arm may provide a counterbalance [6]. - *Caution in solid-organ transplant recipients.* Transplant recipients depend on intentional immunosuppression to prevent graft rejection; the peptide's T-cell reconstitution and exhaustion-reversal effects could in principle work against that goal [6]. - *Limited pregnancy and lactation data.* The clinical database comes from hepatitis, sepsis, cancer and immune-reconstitution populations; dedicated pregnancy and lactation safety studies are absent [2]. - *Null high-quality trial.* The 2025 TESTS phase-3 trial returned no significant mortality benefit in sepsis (HR 0.99, P=0.93) [1]. Expectations should be calibrated to the best available evidence, not only to the earlier positive signals. - *Unregulated supply risk.* Research-grade material obtained outside the pharmaceutical quality chain lacks guaranteed purity, actual content, sterility or identity — a risk independent of the molecule's own pharmacology [2]. - *Injection-site reactions.* Subcutaneous administration predictably produces mild local redness, itching or discomfort, typically transient and self-limiting [2]. ## Where it fits in immune research Among the two compounds on this desk, Thymosin Alpha-1 is the lead and the one with by far the more developed clinical record — four decades of published trials, drug approval in over 35 countries, and a 2025 phase-3 RCT that enrolled over a thousand patients [1][2]. Its story illustrates a recurring pattern in immunopharmacology: a peptide whose mechanism is well characterized and whose earlier positive clinical signals generated genuine excitement, followed by a rigorous large trial that came back null in the most-studied acute setting while leaving open the question in other contexts (chronic hepatitis, cancer adjuvant use). Read alongside [KPV](/kpv) — which works the anti-inflammatory side of host defense rather than the immune-reconstitution side — the two peptides sketch complementary aspects of immune modulation. The [comparison page](/compare) places them side by side. ![Thymosin Alpha-1 immune-signaling diagram — abstract lymphocyte networks in a cold sapphire palette](/images/thymosin-alpha-1.webp) --- An independent literature digest of peer-reviewed immunology research — not a clinic, not a vendor, not a prescription.